Omnicomm buoyed by e-clinical licensing deals

Licensing contracts have given e-clinical solutions provider OmniComm a big first-half boost. The company reports a 51 percent increase in new tech-transfer licenses over first-half 2009, surpassing $6.9 million. Such licensing accounts for 70 percent of new business while it represents 44 percent for the company's business overall.

Software-as-a-service contracts have shown a "steady increase," according to a statement. The company says also that it has "seen some signs of increased spending in the clinical trial R&D arena."

Omnicomm maintains a roughly even presence in life sciences sectors, including biotech, academic/research, CRO, medical device, and pharma.

- see the Omnicomm earnings release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.